Financial Performance & Outlook - Second quarter commercial revenue reached $18.4 million, a 21% increase compared to Q2 2024[8] - A backlog in unpaid provider claims impacted RECELL performance, resulting in an estimated $10 million reduction in RECELL revenue[14] and a ~20% drop in demand[13] - Full-year 2025 revenue guidance revised from $100 million - $106 million to $76 million - $81 million, reflecting a growth of ~19% to 27% compared to FY2024[38] - The company now anticipates cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026[38] - Net loss decreased by 35.7%, and operating expenses decreased by 9.1%[37] Product Impact & Clinical Data - RECELL treatment achieves a significant 36% reduction in hospital Length of Stay (LOS) for patients with deep second-degree burns <30% total body surface area[11, 17] - Cohealyx enables autograft readiness in five to ten days, offering a faster path to healing for full-thickness wounds[11, 24] Market Expansion & Strategy - The U S Total Addressable Market (TAM) for burn and trauma with multi-product strategy is estimated at $3.5 billion[33] - Two major hospitals are expanding RECELL use to burns <20% TBSA, potentially adding ~150 additional patients per month[29] - VAC submissions are now active in ~25% of the ~130 U S burn centers[30]

Core Insights - AVITA Medical, Inc. will host its inaugural Acute Wound Care Showcase 2025 on May 13, 2025, via webcast [1] - The event will feature presentations from key executives and provide an overview of the company's approach to acute wound care [2][3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery [4] - The RECELL® System is a key product, approved by the FDA for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - The company also markets Cohealyx™, a collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix, in the U.S. [4] Product Portfolio - The Acute Wound Care Showcase will highlight the company's product portfolio, including RECELL®, Cohealyx™, and PermeaDerm® [2] - The RECELL System is approved for various applications internationally, including burns and full-thickness skin defects, with regulatory approvals in Australia, Europe, and Japan [5] Event Details - The event will include testimonials from physicians and patients, showcasing the clinical and economic benefits of AVITA's technologies [3] - A live Q&A session will conclude the event, allowing for direct engagement with attendees [3]